Reshaping the HIV treatment and prevention landscape

Jemperli*: enabling next generation Immuno-Oncology with our innovative pipeline Jemperli monotherapy opportunity in niche indications First-in-indication opportunities for Jemperli Novel IO combinations to improve on PD(L)-1 2L dMMR endometrial cancer - approved 2L dMMR pan tumour – filed - 1L endometrial cancer (all comers or dMMR) - RUBY - Ph3 ongoing - 1L ovarian cancer - FIRST - Ph3 ongoing - Multiple myeloma – DREAMM-5 - Ph1 ongoing PD-1 combination with: -TIGIT-planned -CD96 - Ph1 ongoing - PVRIG – planned - - TIM-3 Ph2 ongoing - - LAG-3 - Ph2 ongoing -STING - Ph1 ongoing *Tesaro asset gsk 92

View entire presentation